Group Müller TREM-1 (Triggering Receptor Expressed on Myeloid Cells-1) is an activating innate immune receptor on neutrophils and monocytes / macrophages. We previously described a critical pathogenic role for TREM-1 not only in acute, but also in chronic inflammation, notably, in inflammatory bowel diseases (Schenk et al., J Immunol 2005, J Clin Invest 2007). We generated a Trem1-/- mouse (Weber et al. 2014) to determine the Trem1-mediated effects in atherosclerosis (Zysset et al., Nat Comms 2016) and the development of colitis-associated colorectal carcinoma (Saurer and Zysset et al., Sci Rep 2017). Current research interests include collaborative efforts on the involvement of TREM-1 in neurological disorders, such as stroke (Liu et al., Nat Immunol 2019), and neurodegenerative disorders.